Bahija Jallal: MedImmune's Modern Innovator
This article was originally published in Scrip
When Dr Bahija Jallal stepped out of a conference room full of scientists she knew that her life had changed forever. She had just witnessed a patient personally thanking every person that had worked on a drug she had taken as part of a Phase I trial. Needless to say the trial, and the drug, had worked and the patient was overjoyed. "I remember vividly coming out of that room and thinking that was exactly what I want to do for the rest of my life," she recalls. "That was the beginning of a journey for me. I feel it’s a privilege to do this work."
You may also be interested in...
A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.
One woman CEO is an improvement, but at this rate gender equality won't arrive before immuno-oncology goes generic.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.